-- Statistically significant week 96 results from the Phase 2b HARMONY study of EFX in patients with pre-cirrhotic MASH reported during the first quarter of 2024 -- -- Phase 3 SYNCHRONY Histology and SYNCHRONY Real-World studies in patients with pre-cirrhotic MASH (F2-F3) continue to enroll; SYNCHRONY Outcomes study in patients with compensated cirrhosis due to MASH (F4) on track to be initiated in second quarter of 2024 -- SOUTH SAN FRANCISCO, Calif., May 10, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, In ...

MILWAUKEE, April 2, 2024 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Akero (Nasdaq: AKRO). The investigation results from inaccurate statements Akero may have made regarding its business operations and prospects. Click here to learn more about the investigation: https://www.ademilaw.com/case/akero-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you. The investigation focuses on Akero's representations regarding its Phas ...

SOUTH SAN FRANCISCO, Calif., March 08, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today the closing of its previously announced underwritten public offering of 12,650,000 shares of its common stock at a public offering price of $29.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to a ...

As reported previously, the addition of EFX to GLP-1 receptor agonist therapy had a safety and tolerability profile comparable to that of EFX alone and led to statistically significant improvements in non-invasive markers of liver injury and fibrosis and of metabolic health Results indicate potential of EFX to improve resolution of steatohepatitis and fibrosis for patients with MASH and type 2 diabetes already taking a GLP-1 receptor agonist SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- A ...

SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a public offering price of $29.00 per share. All of the shares in the offering are being offered by Akero Therapeutics. In addition, Akero Therapeutics has gr ...

Akero Therapeutics, Inc. (AKRO) announced a statistically significant histological improvement in the primary endpoint of its mid-stage study, evaluating the efficacy and safety of efruxifermin (EFX) in patients with pre-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH), fibrosis stage 2 or 3, at week 96.EFX, the company’s lead product candidate, is being developed for a serious liver disease caused by metabolic dysregulation that does not have any approved therapies.We remind the investors ...

SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today that it has commenced an underwritten public offering of $300.0 million of shares of its common stock. All of the shares in the proposed offering are being offered by Akero Therapeutics. In addition, Akero Therapeutics intends to grant the underwrit ...

alfexe/iStock via Getty Images Akero Therapeutics, Inc. (NASDAQ:AKRO) has been able to report positive results from its phase 2b HARMONY study, which used its drug efruxifermin [EFX] for the treatment of patients with pre-cirrhotic MASH or Metabolic dysfunction-associated steatohepatitis with stage 2 or 3 fibrosis. The significance of this is that it is already in the process of testing out this drug in a phase 3 program known as SYNCHRONY. Patients have already been dosed in the first two phase 3 studi ...

Core Insights - Akero Therapeutics released preliminary topline week 96 results from the Phase 2b HARMONY study, demonstrating significant efficacy of efruxifermin (EFX) in improving fibrosis in patients with pre-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) [1][2][16] - The study showed that 75% of patients in the 50mg EFX group and 46% in the 28mg EFX group achieved at least a one-stage improvement in fibrosis without worsening of MASH, compared to 24% in the placebo group [1][3] - EFX also demonstrated a 2-stage improvement in fibrosis for 36% of the 50mg group and 31% of the 28mg group, significantly higher than the placebo rate of 3% [2][3] Efficacy Results - The primary endpoint of the study was met, with the 50mg EFX group showing a 41% improvement at week 24, which increased to 75% at week 96 [1][3] - The placebo-adjusted effect size for fibrosis improvement without worsening of MASH increased from 21% to 52% for the 50mg EFX group between week 24 and week 96 [4][5] - Among patients with advanced F3 fibrosis, 68% of the 50mg EFX group experienced at least a one-stage improvement in fibrosis without worsening of MASH, compared to 14% for placebo [5][9] Safety and Tolerability - EFX was generally well-tolerated, with no deaths reported and serious adverse events balanced across dose groups [11][12] - The most common adverse events were mild gastrointestinal issues, which were transient [11][12] Future Outlook - Akero is optimistic about the ongoing Phase 3 SYNCHRONY studies, which will further evaluate EFX's efficacy in broader patient populations [6][18] - The company plans to report results from the SYMMETRY study, which focuses on patients with compensated cirrhosis, in the first quarter of 2025 [12][18]

Akero Therapeutics, Inc. (AKRO) closed the last trading session at $26.99, gaining 28.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $42.88 indicates a 58.9% upside potential.The average comprises eight short-term price targets ranging from a low of $33 to a high of $60, with a standard deviation of $10.60. While the lowest estimate indicates an increase of 22.3% from the curre ...